Investing.com - ADMA Biologics Inc (NASDAQ: ADMA) reported first quarter EPS of $-0.0600, in line with the analyst estimate of $-0.0600. Revenue for the quarter came in at $49.98M versus the consensus estimate of $45.93M.
Guidance
ADMA Biologics Inc sees FY 2023 revenue of $250.0000M versus the analyst consensus of $258.7000M.
ADMA Biologics Inc's stock price closed at $3.1100. It is down -14.7900% in the last 3 months and up 107.3300% in the last 12 months.
ADMA Biologics Inc saw 0 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See ADMA Biologics Inc's stock price’s past reactions to earnings here.
According to InvestingPro, ADMA Biologics Inc's Financial Health score is "fair performance".
Check out ADMA Biologics Inc's recent earnings performance, and ADMA Biologics Inc's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar